Industry Briefs: October 15, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Paladin Labs has entered into a licensing agreement with QRxPharma whereby Paladin received the exclusive rights to market and sell Moxduo, for treating acute pain, in Canada. Read More
Theravance and Merck & Co. have agreed to discover, develop, and commercialize small-molecule therapeutics directed toward a target being investigated for treating of hypertension and heart failure. Read More
People News
Amgen has appointed Cynthia Patton as senior vice-president and chief compliance officer. Read More
Sirona Biochem has named Neil Belenkie as CEO. Read More
Unilife has expanded its commercial development team with the appointment of four senior executives. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
